New Report: R&D Trends: Allergic Rhinitis - Immunotherapy takes a rising share of the pipeline

May 27, 2011 - PRLog -- Introduction

The 2011 pipeline shows strong interest in immunotherapy, which makes up 42% of products in development. Advancements in clinical trials and key partnerships are increasing exposure of this class. In this largely stable market, areas of innovation exist with nasal antihistamine/corticosteroid combinations remaining highly anticipated, while a number of novel targeted therapies raise skepticism.

Features and benefits

* Assessment of the allergic rhinitis pipeline, drawing out trends by class and the potential to address unmet needs
* Analysis of clinical trial design, highlighting innovation and anticipated future changes, with a focus on recent developments in immunotherapy
* Discussion of novel early stage approaches and the future of treatment in allergic rhinitis, with insight from key opinion leaders


Highlights

Datamonitor has identified 60 products in development for allergic rhinitis. The late-stage pipeline is heavily skewed towards immunotherapy, which makes up 12 of 13 Phase III products. Immunotherapy shows the greatest innovation, with considerable change to clinical trials, and increased focus on sublingual tablet franchises.
Discussions with key opinion leaders reveal a largely stable market for symptomatic treatment; however, areas of innovation exist, such as the development of combination products. Analysis of comparator therapies highlights areas of unmet need.
A number of novel targeted therapies are moving through the pipeline, and two CRTH2 antagonists have reached Phase II. Key opinion leaders express skepticism over their clinical viability, with efficacy expected to fall short of established treatment classes. However, they may find a place in the treatment of select groups of patients.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/158698_rd_trends_allergic_rhin...
------------------------------------------------------------

Your key questions answered

* Which characteristics of symptomatic treatments can be improved upon, and what would it take to create a new gold standard?
* What are the driving forces behind allergic rhinitis clinical trial design and how has it evolved?
* To what extent will the growing investment in immunotherapy change the future of treatment?
* Is there value in novel targeted therapies or will current treatments continue to dominate?


Report Table of Contents:

Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
CLINICAL PIPELINE OVERVIEW
Allergen immunotherapy dominates late-stage pipeline
Analysis by formulation demonstrates innovation in the pipeline
Late-stage discontinued development compounds
Epinastine nasal formulation (Inspire Pharmaceuticals)
Loratadine/montelukast (Merck)
Sublingual immunotherapies (Greer)
TARGET PRODUCT PROFILE
Telfast/Allegra (fexofenadine; Sanofi-Aventis)
Pivotal trial data for Telfast/Allegra
Nasonex (mometasone; Merck & Co.)
Pivotal trial data for Nasonex
Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN ALLERGIC RHINITIS
Trends in clinical trial endpoints
Symptom scores
Allergy challenges tackle seasonal variations
Study populations
Comparator drugs
Drug development guidelines in allergen immunotherapy
Typical allergic rhinitis clinical trials
Symptomatic treatment
Allergen immunotherapy
Future developments in clinical trial design
INNOVATIVE EARLY-STAGE APPROACHES
Sublingual immunotherapy franchises
Antihistamine combinations
Novel targeted therapies
THE FUTURE OF TREATMENT IN ALLERGIC RHINITIS
Combination antihistamine/corticosteroid therapy
Sublingual shift in immunotherapy
BIBLIOGRAPHY
Journal papers
Websites
APPENDIX
Contributing experts
Conferences attended
Report methodology

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.